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anticoagulation prevented this complication. Continuing ef-
forts to define the optimal oral anticoagulant therapy to
minimize the chances of stroke and bleeding are still nec-
essary.
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Discussion
Dr Cary Akins (Boston, Mass). I congratulate Dr Bando on
this nice presentation of his continuing evaluation of the effect of
concomitant maze procedures on the results of mitral valve sur-
gery, which was similar to his presentation at this meeting a year
ago. This year’s presentation enlarges last year’s study with the
inclusion of about 40 patients undergoing the combination of the
maze procedure and valve replacement and adds about 600 pa-
tients who had mechanical MVR from 1977 to 1992, none of
whom had a maze procedure. This study concludes, as last year’s
study did, that sinus rhythm is associated with better long-term
neurologic results but that sinus rhythm apparently has no demon-
strable effect on long-term survival.
I have several questions about the study design, the first con-
cerning the mechanical prostheses implanted because we know
that different prostheses have different thrombogenic potentials.
Did all of the patients in this study going back to 1977 receive the
same mechanical prosthesis? If different prostheses were used, was
prosthesis type inserted as a variable in the Cox analysis?
Dr Bando. Thank you very much, Dr Akins, for your excellent
questions. Regarding the type of valves, among these 812 patients,
533 patients had a St Jude mechanical valve, and the remaining
valves include the CarboMedics valve in 125 patients and, re-
cently, the ATS valve in 47 patients. Earlier in our experience, the
Bjo¨rk-Shiley valve was used in 70 patients, and the Omniscience
valve was used in 23 patients. We did analyze the type of valves
as potential predictors in univariate and multivariate analyses, and
these were entered into a Cox proportional hazards model, but
none of the valve types came out as a risk factor for either late
mortality or late stroke.
Dr Akins. My second question focuses on the effect of oblit-
eration of the left atrial appendage on late stroke. The authors
include in their statistical analysis of this part of the study patients
who had a concomitant maze procedure. Wouldn’t it be better to
eliminate the maze patients and analyze only patients who had a
MVR with or without obliteration of the left atrial appendage?
Dr Bando. That is a very excellent point, Dr Akins. Removing
185 patients, we have 627 patients undergoing MVR alone, and if
Appendix Figure 1. Freedom from stroke in patients with sinus
rhythm after the maze procedure versus freedom from stroke in
those in native sinus rhythm.
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you compared those patients with or without closure of the left
atrial appendage, actually half of them, 320, have the left atrial
appendage closed, whereas the remaining 307 patients had the left
atrial appendage left open. Of those, there are 69 strokes we have
so far. Again, 43 patients had the left atrial appendage closed, and
the remaining 26 were left open. Therefore, looking at those data
in this subset of the whole group, there is no difference and no
positive effect on the prevention of late stroke.
Dr Akins. In contrast to the program book abstract, the manu-
script states that of the 72 patients who had a late stroke, 62 had an
INR of only greater than 1.8 and not 2.3. In fact, half of the
patients who had a stroke had an INR of 2.2 or less, a level that
would be quite low for North American patients with a mechanical
mitral valve, particularly those with persistent atrial fibrillation.
Have you changed your target INR levels for these patients?
Dr Bando. Actually not, because the second to last slide shows
that if the target level is coming out over 3, we are going to have
more and more patients with major bleeding, and in our society
with the Japanese circulation, we are about to make guidelines of
what would be an adequate target level, and it ends up to be
between 2 to 3 or 1.8 to 2.8.
Dr Akins. I question using patients going back 25 years as a
cohort against which to compare patients having concomitant
maze operations since 1992. Earlier patients might have had sub-
stantially different operations, prostheses, and other risk factors for
stroke. Indeed, earlier year of operation is a significant predictor of
late stroke. How do you think the addition of this early surgical
group has really added to the strength of your study?
Dr Bando. That is a good point. The observation period is
totally different for the maze group studied since 1992 and those
patients operated on before that, close to 24 years. Numerous
changes have happened in our institution. First, we used the
bioprosthetic valve, the Ionescu-Shiley valve, extensively for all
generations between 1980 and 1984 and then changed to using the
Carpentier-Edwards bioprosthetic valve, but only for patients over
70 years old. Otherwise, we all use mechanical valves. That is the
major change. And also, even after 1992, we used 3 different maze
techniques. That might have an effect on the results. I agree with
you.
Dr Akins. There is no doubt that patients with atrial fibrillation,
even those without mitral valve disease, have a greater risk of
stroke and are best treated with long-term anticoagulation. Al-
though my bias is to agree with the authors’ premise that mainte-
nance of sinus rhythm in addition to anticoagulation for mechan-
ical mitral prostheses might yield better neurologic outcomes, I am
not convinced that adding this earlier surgical group has made this
study prove that point.
Dr Bando. That is a very good point, and that is the primary
reason we are going to do a prospective randomized study to try to
find out what would be the best anticoagulation strategy comparing
warfarin versus warfarin plus aspirin, and we are going to start that
pretty soon.
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